It could suppress the proliferation of medulloblastoma cells harboring the SMO D473H mutation, which is derived from a patient who relapsed after an initial response to vismodegib treatment.545 The SMO inhibitor taladegib can bind to and inhibit SMO D473H activity. The gene discussed is SMO; the disease is medulloblastoma.